New targets for NAFLD
Obese NAFLD children and adolescents: high BMI predicts liver fibrosis
NAFLD and incident chronic kidney disease
Diabetic kidney disease, cardiovascular disease and NAFLD
Chronic vitamin C deficiency decreases NAFLD progression
This animal study aimed to reveal the role of vitamin C in NAFLD progression
MAFLD: brain-gut-liver axis and insulin resistance
There are many complex physio-pathologic connections within the brain, gut, and liver axis. This review by E. Rebelos et al. (University of Turku, Finland) is focused on the early pathophysiology of brain, gut, and liver axis in the context of insulin resistance and specifically addresses two pillars of hepatic insulin resistance....
FIB-4 and NFS: which performance?
M. Castellana et al. (National Institute of Gastroenterology "Saverio de Bellis," Research Hospital, Italy) conducted a meta-analysis to assess the performance of the FIB-4 and NFS scores, the 2 most common non-invasive tools, for the appropriate selection of subjects with AF for biopsy. A total of 18 studies evaluating 12,604 subjects were included...
Enhanced liver fibrosis test and recognition of liver fibrosis
This retrospective cross-sectional study was conducted among patients recruited from a large, community-based hospital system's outpatient liver clinic from 2001 to 202 in order to determine the performance of the enhanced liver fibrosis (ELF) test as a non-invasive test for assessment of liver fibrosis among patients with NAFLD...
NASH Epidemic: a call to action
NAFLD and NASH are common conditions with a rising burden. As pointed out by F. Kanwal et al. (Baylor College of Medicine, and Michael E. DeBakey Veterans Affairs Medical Center, Houston,USA), “yet there are significant management gaps between clinical guidelines and practice in patients with NAFLD and NASH. Further, there is no single...
MAFLD and lipoprotein metabolism
Identifying patients with high-risk NASH: three ultrasound markers
Identifying patients with high-risk-NASH who are candidates for pharmacologic therapy remains a challenge. K. Sugimoto et al. (Tokyo Medical University, Japan) aimed to develop a score to identify patients with a NAFLD activity score of 4 or greater and clinically significant fibrosis...